List of works - Peter J. Barry

After the Celebrations: Lessons from the New Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy

scientific article published on 01 February 2019

Anabolic agent use in adults with cystic fibrosis.

scientific article published on 22 September 2015

Androgens, exercise capacity, and muscle function in cystic fibrosis

scientific article published on 8 August 2008

Bronchodilators in cystic fibrosis: a critical analysis

scientific article

CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials

scientific article published on 03 May 2019

CFTR modulator therapy in patients with cystic fibrosis and an organ transplant

scientific article published on 25 April 2018

Central cyanosis on a psychiatric unit treated at the Salford Royal Hospital

scientific article published on 25 July 2014

Challenge for a new era-importance of ensuring accuracy of genotype in cystic fibrosis registries

scientific article published on 8 April 2016

Cystic fibrosis transmembrane conductance regulator modulators: the end of the beginning

scientific article published on 31 March 2015

Discordance between clinical, physiological, and radiological measures in cystic fibrosis

scientific article

Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease

scientific article published in July 2014

Highlights from the 30th North American Cystic Fibrosis Conference, Orlando 2016.

scientific article published on 14 March 2017

Influenza B outbreak at an adult cystic fibrosis centre - Clinical impact and factors influencing spread

scientific article published on 19 June 2020

Ivacaftor for cystic fibrosis.

scientific article

Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?

scientific article published on 01 July 2015

New and Emerging Treatments for Cystic Fibrosis

scientific article published on July 2015

Orkambi in patients with severe disease - Bumps in the road to CFTR modulation

scientific article published on 19 April 2017

Panton-Valentine Leukocidin-positive Staphylococcus aureus: a potentially significant pathogen in cystic fibrosis.

scientific article published on 13 April 2014

Pneumothorax in cystic fibrosis: beyond the guidelines.

scientific article

Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis

scientific article

Relationship between pulmonary hyperinflation and dyspnoea severity during acute exacerbations of cystic fibrosis

scientific article published on 11 September 2016

Skin contamination leading to falsely elevated fingerprick tobramycin levels in a patient taking dry powder inhaled tobramycin

scientific article published on 02 May 2014

Sweat chloride is not a useful marker of clinical response to Ivacaftor.

scientific article published on 20 November 2013

Tezacaftor and ivacaftor for the treatment of cystic fibrosis

scientific article published on 31 October 2019

The changing landscape of cystic fibrosis: new therapies, challenges and a global pandemic

scientific article published on 15 September 2020

List of works by Peter J. Barry

After the Celebrations: Lessons from the New Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy

Anabolic agent use in adults with cystic fibrosis.

Androgens, exercise capacity, and muscle function in cystic fibrosis

Bronchodilators in cystic fibrosis: a critical analysis

CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials

CFTR modulator therapy in patients with cystic fibrosis and an organ transplant

Central cyanosis on a psychiatric unit treated at the Salford Royal Hospital

Challenge for a new era-importance of ensuring accuracy of genotype in cystic fibrosis registries

Cystic fibrosis transmembrane conductance regulator modulators: the end of the beginning

Discordance between clinical, physiological, and radiological measures in cystic fibrosis

Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease

Highlights from the 30th North American Cystic Fibrosis Conference, Orlando 2016.

Influenza B outbreak at an adult cystic fibrosis centre - Clinical impact and factors influencing spread

Ivacaftor for cystic fibrosis.

Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?

New and Emerging Treatments for Cystic Fibrosis

Orkambi in patients with severe disease - Bumps in the road to CFTR modulation

Panton-Valentine Leukocidin-positive Staphylococcus aureus: a potentially significant pathogen in cystic fibrosis.

Pneumothorax in cystic fibrosis: beyond the guidelines.

Progress in Definition, Prevention and Treatment of Fungal Infections in Cystic Fibrosis

Relationship between pulmonary hyperinflation and dyspnoea severity during acute exacerbations of cystic fibrosis

Skin contamination leading to falsely elevated fingerprick tobramycin levels in a patient taking dry powder inhaled tobramycin

Sweat chloride is not a useful marker of clinical response to Ivacaftor.

Tezacaftor and ivacaftor for the treatment of cystic fibrosis

The changing landscape of cystic fibrosis: new therapies, challenges and a global pandemic